Trials / Completed
CompletedNCT00540124
Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Pilot Study to Evaluate the Efficacy and Safety of Tadalafil and Tamsulosin Once-a-Day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Male
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this clinical trial is to evaluate the change in the International Prostate Symptom Score (IPSS) total score from the beginning of the study to the end of the study for subjects randomized to tadalafil 5mg once a day dosing and placebo once a day dosing for 12 weeks of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tadalafil | 5 mg once a day |
| DRUG | Placebo | once a day |
| DRUG | Tamsulosin | 0.2 mg once a day |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2007-10-05
- Last updated
- 2010-11-25
- Results posted
- 2009-07-20
Locations
5 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00540124. Inclusion in this directory is not an endorsement.